{
    "clinical_study": {
        "@rank": "21758", 
        "arm_group": [
            {
                "arm_group_label": "Intron A, HDI", 
                "description": "High-dose interferon alfa (Intron A, HDI)"
            }, 
            {
                "arm_group_label": "Sylatron", 
                "description": "Pegylated alfa-interferon 2b (Sylatron, PEG IFN)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the compliance with and perceptions of treatment, as well as health-related\n      quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN\n      therapy."
        }, 
        "brief_title": "An Observational Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon A Versus Sylatron", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is male or female at least 18 years of age\n\n          -  Patient has had surgically resected melanoma and plans to                receive\n             adjuvant therapy with HDI or PEG IFN\n\n          -  Patient is willing and able to give written informed consent\n\n          -  Patient is willing to comply with all study requirements\n\n        Exclusion Criteria:\n\n          -  Patient is unable or unwilling to complete QoL questionaire or compliance   diary\n\n          -  Patient has a history of anaphylaxis due to any interferon alpha product\n\n          -  Patient has autoimmune hepatitis\n\n          -  Patient has decompensated liver disease (Child-Pugh score>6 ( Class B and C)\n\n          -  Patient has a history of neuropsychiatric disorder (including depression) that, in\n             the judgment of the investigator, may impair the patient's ability to successfully\n             complete treatment or protocol-related requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with surgically resected melanoma receiving adjuvant therapy with HDI or PEG IFN\n        thherapy"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986712", 
            "org_study_id": "Merck MISP 50422"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferons", 
                "Peginterferon alfa-2b"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "contact": {
                "email": "Rosemarie.cabral@sluhn.org", 
                "last_name": "Rose M Cabral, RN", 
                "phone": "484-503-4151"
            }, 
            "contact_backup": {
                "email": "Sanjiv.agarwala@sluhn.org", 
                "last_name": "Sanjiv Agarwala, MD", 
                "phone": "484-503-4500"
            }, 
            "facility": {
                "address": {
                    "city": "Bethlehem", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "18017"
                }, 
                "name": "St Luke's University Hospital and Health Network"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "An Observational Pilot Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon Alfa Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma", 
        "overall_contact": {
            "email": "Rosemarie.Cabral@sluhn.org", 
            "last_name": "Rose Cabral, RN, BSN, OCN", 
            "phone": "484-503-4151"
        }, 
        "overall_contact_backup": {
            "email": "Tracy.Butryn@sluhn.org", 
            "last_name": "Tracy Butryn, MS, CCRP", 
            "phone": "484-526-5190"
        }, 
        "overall_official": {
            "affiliation": "St. Luke's University Health Network", 
            "last_name": "Sanjiv Agarwala, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate compliance with administration of standard HDI versus PEG IFN for patients with surgically resected melanoma in need of adjuvant therapy", 
            "measure": "Evaluate Compliance with Standard High Dose Interferon (HDI) versus Sylatron", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986712"
        }, 
        "responsible_party": {
            "investigator_affiliation": "St. Luke's Hospital and Health Network, Pennsylvania", 
            "investigator_full_name": "Sanjiv Agarwala, MD", 
            "investigator_title": "Chief of Medical Oncology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare QOL for patients on standard HDI versus PEG IFN using chemotherapy convenience and satisfaction questionaire (CCSQ) and to evaluate the treatment-related side effects that may impact the patients health-related QOL using Functional Assessment of Cancer Therapy of Biologic Response Modifier (FACT-BRM)", 
                "measure": "Compare Quality of Life (Qol)for patients on HDI versus PEG IFN", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To assess the frequency of Grade 3 and 4 toxicities, according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) for patients on standard HDI versus PEG IFN", 
                "measure": "Assess the frequency of Grade 3 and Grade 4 Toxicities", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To examine reasons for patients' choice of treatment HDI versus PEG IFN, for those case in which patients are presented with a choice of either treatment option", 
                "measure": "Examine the Reasons for Patients' Choice of Treatment with HDI versus PEG IFN", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "St. Luke's Hospital and Health Network, Pennsylvania", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanjiv Agarwala, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}